

ORIGINAL PAPER

ORYGINALNY ARTYKUŁ NAUKOWY

**CONTRIBUTION OF BIOLOGICAL TREATMENT TO THE FINAL EFFECT OF
REHABILITATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS**

**UDZIAŁ LECZENIA BIOLOGICZNEGO W KOŃCOWYM EFEKCIE
REHABILITACJI U PACJENTÓW Z ZESZTYWNIAJĄCYM ZAPALENIEM
STAWÓW KRĘGOSŁUPA**

**Pavol Nechvátal^{1(A,B,D,E,F)}, Lucia Demjanovič Kendrová^{1(C,D,E)}, Wioletta Mikulakova^{1(D,E,F)},
Jakub Čuj^{1(A,E,F)}**

¹Department of Physiotherapy, Faculty of Health Care, University of Presov, Slovakia

Nechvátal P, Demjanovič Kendrová L, Mikulakova W, Čuj J. Contribution of biological treatment to the final effect of rehabilitation in patients with ankylosing spondylitis. Health Prob Civil. <https://doi.org/10.5114/hpc.2024.139341>

Tables: 4

Figures: 1

References: 30

Submitted: 2024 Feb 7

Accepted: 2024 Apr 29

Address for correspondence / Adres korespondencyjny: Lucia Demjanovič Kendrová, Department of Physiotherapy, Faculty of Health Care, University of Presov, Partizánska 1, 080 01 Prešov, Slovakia, e-mail: lucia.kendrova@unipo.sk, phone: +421517562401

ORCID: Pavol Nechvátal <https://orcid.org/0000-0003-2387-6745>, Lucia Demjanovič Kendrová <https://orcid.org/0000-0003-4008-8185>, Wioletta Mikulakova <https://orcid.org/0000-0002-1189-8771>, Jakub Čuj <https://orcid.org/0000-0003-2095-4816>

Copyright: © John Paul II University in Białá Podlaska, Pavol Nechvátal, Lucia Demjanovič Kendrová, Wioletta Mikulakova, Jakub Čuj. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons AttributionNonCommercialShareAlike 4.0 International (CC BY-NC-SA 4.0) License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Summary

Background. Ankylosing spondylitis (AS) primarily targets the spine and sacroiliac joints, manifesting as a chronic inflammatory autoimmune condition. The aim of the study was to investigate the benefits of biological therapy on the final effect of rehabilitation in patients with AS.

Material and methods. A total of 60 patients with a mean age of 45 years who were diagnosed with stage II-III AS participated in the study. In addition to rehabilitation, 30 patients received conventional and 30 biological treatment. The functional disability was assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI) questionnaire and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questionnaire was used to assess disease activity.

Results. Significant reductions in functional disability and disease activity were observed in both groups of patients ($p < 0.001$) after treatment (conventional/biological and rehabilitation). Statistical processing of the outcome results revealed that patients in the second group (with biological treatment) had a significantly lower rate of functional disability (BASFI=31) after

treatment compared to the first group of patients (BASFI=35) ($p=0.032$). Disease activity was comparable in both groups of patients after treatment, but no significant difference was found ($p=0.063$).

Conclusions. The study demonstrated that rehabilitation has a positive effect on functional disability and disease activity, with significantly better outcomes found in the biological therapy group of patients compared to the conventional therapy group of patients.

Keywords: biological therapy, functional disability, ankylosing spondylitis, disease activity, physical activity

Streszczenie

Wprowadzenie. Zesztywniające zapalenie stawów kręgosłupa (ZZSK) atakuje głównie kręgosłup i stawy krzyżowo-biodrowe, objawiając się jako przewlekła zapalna choroba autoimmunologiczna. Celem badań była ocena wpływu terapii biologicznej na końcowy efekt rehabilitacji u pacjentów z ZZSK.

Materiał i metody. W badaniu wzięło udział 60 pacjentów w wieku wynoszącym średnio 45 lat, u których zdiagnozowano ZZSK w stadium II-III. Oprócz rehabilitacji, 30 pacjentów otrzymało leczenie konwencjonalne, a 30 leczenie biologiczne. Niepełnosprawność funkcjonalną oceniano za pomocą kwestionariusza Bath Ankylosing Spondylitis Functional Index (BASFI; wskaźnik funkcjonalności ZZSK), a do oceny aktywności choroby wykorzystano kwestionariusz Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; wskaźnik aktywności ZZSK).

Wyniki. Zaobserwowano istotne zmniejszenie niepełnosprawności funkcjonalnej i aktywności choroby w obu grupach pacjentów ($p<0,001$) po leczeniu (konwencjonalnym/biologicznym i rehabilitacyjnym). Analiza statystyczna wyników wykazała, że pacjenci w drugiej grupie (otrzymujący leczenie biologiczne) mieli istotnie niższy wskaźnik niepełnosprawności

funkcjonalnej (BASFI=31) po leczeniu w porównaniu z pierwszą grupą pacjentów (BASFI=35) ($p=0,032$). Aktywność choroby była porównywalna w obu grupach pacjentów po leczeniu, ale nie stwierdzono istotnej różnicy ($p=0,063$).

Wnioski. Badanie wykazało, że rehabilitacja ma pozytywny wpływ na niepełnosprawność funkcjonalną i aktywność choroby, z istotnie lepszymi wynikami w grupie pacjentów leczonych biologicznie w porównaniu z grupą pacjentów leczonych konwencjonalnie.

Słowa kluczowe: terapia biologiczna, niepełnosprawność funkcjonalna, zeszywniające zapalenie stawów kręgosłupa, aktywność choroby, aktywność fizyczna

Introduction

Ankylosing spondylitis (AS) primarily targets the spine and sacroiliac joints, manifesting as a chronic inflammatory autoimmune condition. The condition is marked by the formation of new bone in the axial skeleton and progressive structural deterioration in the spine, sacroiliac joint, and, potentially, peripheral joints. Additionally, extra-articular manifestations such as uveitis, psoriasis, inflammatory bowel disease, and cardiovascular and pulmonary abnormalities may manifest in individuals with this condition [1]. AS predominantly affects young males and is characterized by joint pain and stiffness (ankylosis), accompanied by inflammation at tendon insertions [2,3].

The treatment focus is not only on affecting the inflammatory process but also on preventing structural damage and preserving function. The standard treatment, apart from rehabilitation, consists of the administration of non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). Despite treatment with NSAIDs, treatment with tumor necrosis factor α (TNFis) inhibitors (biological treatment) is recommended in patients with high disease activity [4]. Factors indicating a positive response

to TNFis include shorter disease duration, patients aged ≤ 40 years, lack of enthesitis, HLA – B27 positivity, good functional status, elevated CRP levels [5], and male gender [6]. Contraindications to TNFis include active infection, tuberculosis, advanced heart failure, lupus, multiple sclerosis, and cancer. Biologic medications may be ineffective in AS patients with concurrent vertebral fractures or degenerative intervertebral disc disease [1].

Siman et al. [7] propose a four-phase sequenced rehabilitation protocol for patients with AS. Phase 1 is based on pain relief and improve mobility, phase 2 aims to restore flexibility and postural re-training, phase 3 focuses on aerobic conditioning and strengthening, and phase 4 on activities of daily living and maintenance of function.

Pain is a prominent symptom suffered by AS patients. Liang et al. [8] reported in their study that water therapy has been shown to decrease disease activity and alleviate pain in these patients. However, it does not appear to improve functional capacity or spinal mobility.

Spinal mobility can be improved by physical exercise. However, if spinal mobility exercises, including stretching and strengthening exercises, are combined with soft-tissue mobilization, this translates into significant improvements at the mobility, functional level, lumbar lateral flexion, disease activity, reduction of disability and increasing the quality of life [9]. Equally important is the performance of balance and stability exercises, which, when combined with spa, can increase the duration of maintaining balance and enhance the benefits of physiotherapy [10].

Aim of the work

The aim of this study was to investigate the benefits of biological treatment on the final effect of rehabilitation in patients with ankylosing spondylitis.

Material and methods

Participants

A total of 60 patients (54 males and 6 females) diagnosed with stage II-III AS participated in the study. The mean age of the patients was 45 years, the youngest was 25, and the oldest was 68. All patients were instructed in the conduct of the study and consented to the use of the data obtained for research purposes. 30 patients received treatment at the rheumatology outpatient clinic of a hospital and 30 at the highly specialized rheumatology unit focused on biological treatment of resistant inflammatory rheumatic diseases. All patients from both facilities were included in the study in a consecutive manner with their consent, and the procedures followed were in accordance with the Declaration of Helsinki of 1975, revised in 2000.

Therapeutic intervention

Conventional treatment consists of using NSAIDs, DMARDs (methotrexate), and corticosteroids. Dosing and duration of treatment are determined by the attending physician based on individual patient's needs.

Biological treatment was individually indicated (dosing and length) according to the disease, patient reaction on treatment, and to the used biological medicines type, and the treatment lasted for a long time. The administration frequency ranged from once per week to once per month, depending on the active substance used. Adalimumab and Etanercept were mostly administered.

The patients underwent physiotherapy 2-3 times per week, supervised by a physiotherapist for 3 weeks. Conventional methods such as kinesiotherapy and manual techniques were applied within physiotherapy, targeting the maintenance or improvement of spine and peripheral joint mobility, releasing shortened muscles, strengthening flaccid muscles, aiming at muscle balance recovery, and, last but not least, maintaining respiratory performance. Due to analgetic and myorelaxing effects, physical therapy, especially electrotherapy and mechanotherapy, was also applied. All of the physiotherapy and physical therapy procedures were applied according to patient's individual needs and the attending physician's indications. The patients exercised twice daily at home during the research, which lasted 5-6 months.

Measured variables

From the total number of patients (n=60), 2 groups were formed. The first group (n=30) consisted of patients who received conventional treatment. The second group (n=30) consisted of patients who received biological therapy.

The degree of functional disability and disease activity were assessed in the patients. Functional disability was assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI) questionnaire. The questionnaire consisted of 10 questions, each of which was scored between 0 and 10 points. The resulting scores ranged from 0 to 100, with 0 indicating no disability and 100 indicating maximum functional disability [11,12].

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questionnaire was used to assess disease activity. The questionnaire consisted of 6 questions, each of which was scored between 0 and 10 points. The final score ranged from 0 to 60, with 0 and 60 reflecting no and maximal disease activity, respectively [12,13].

Questionnaires were completed at baseline and after completion of 5-6 months of conventional rheumatology/biological treatment. Simultaneously, all patients underwent rehabilitation in an outpatient form, which consisted of kinesiotherapy and physical therapy.

Data analysis

The data obtained from the completed questionnaires were statistically processed and evaluated using a paired and unpaired T-test for independent samples after performing normality tests. The monitored data was processed using the statistical software SPSS PASW - Statistics version 18.

Results

Patients in both groups experienced a significant reduction in functional disability and disease activity ($p < 0.001$) after treatment (conventional/biological and rehabilitation) (Tables 1 and 2).

Table 1. Statistical evaluation of the input and output results of Group 1

Questionnaire	Input outcome (n=30)	Output outcome (n=30)	<i>p</i>
BASFI	52±11.17 (76-29)	35±7.31 (48-22)	<0.001
BASDAI	22±5.26 (36-15)	17.5±5.06 (24-6)	<0.001

Notes: Group 1 – the group of patients with conventional treatment, BASFI – Bath Ankylosing Spondylitis Functional Index, BASDAI – Bath Ankylosing Spondylitis Disease Activity Index.

Table 2. Statistical evaluation of the input and output results of Group 2

Questionnaire	Input outcome (n=30)	Output outcome (n=30)	<i>p</i>
BASFI	51.5±11.53 (76-29)	31±4.52 (42-24)	<0.001
BASDAI	29±8.62 (41-17)	19±5.23 (28-7)	<0.001

Notes: Group 2 – the group of patients with biological treatment, BASFI – Bath Ankylosing

Spondylitis Functional Index, BASDAI – Bath Ankylosing Spondylitis Disease Activity Index.

Based on the baseline findings, there was no notable disparity in the degree of functional disability between the two patient groups ($p>0.05$). However, the biological therapy group of patients was found to have significantly higher disease activity ($p<0.05$), median BASDAI = 29, before the start of treatment, whereas the median BASDAI was equal to 22 in the conventional therapy group of patients (Table 3).

Table 3. Statistical evaluation of the initial results of Groups 1 and 2

Questionnaire	Group 1 (n=30)	Group 2 (n= 0)	<i>p</i>
BASFI	52±11.17 (76-29)	51.5±11.53 (76-29)	0.450
BASDAI	22±5.26 (36-15)	29±8.62 (41-17)	0.012

Notes: Group 1 – the group of patients with conventional treatment, Group 2 – the group of patients with biological treatment, BASFI – Bath Ankylosing Spondylitis Functional Index, BASDAI – Bath Ankylosing Spondylitis Disease Activity Index.

Statistical processing of the outcome results revealed that the biological therapy group of patients had a significantly lower rate of functional disability (BASFI=31) after 5-6 months of treatment compared to the conventional therapy group of patients (BASFI=35) ($p=0.032$). Disease activity was comparable in the two groups of patients after treatment, with no significant difference ($p=0.063$) (Table 4), despite the fact that the biological therapy group of patients had a significantly higher rate of disease activity before treatment. In the conventional

therapy group of patients, BASDAI improved by an average of 4.5, and in the biological therapy group, by up to 10 points.

Table 4. Statistical evaluation of the outcome results of Groups 1 and 2

Questionnaire	Group 1 (n=30)	Group 2 (n=30)	<i>p</i>
BASFI	35±7.31 (48-22)	31±4.52 (42-24)	0.032
BASDAI	17.5±5.06 (24-6)	19±5.23 (28-7)	0.063

Notes: Group 1 – the group of patients with conventional treatment, Group 2 – the group of patients with biological treatment, BASFI – Bath Ankylosing Spondylitis Functional Index, BASDAI – Bath Ankylosing Spondylitis Disease Activity Index.

Discussion

International guidelines advise that patients with AS should undergo lifelong physiotherapy, as physical activity and movement are crucial for optimizing health throughout the course of the disease [14]. According to the recommendations of Millner et al. [15], complex physical activities can be employed to sustain a favorable clinical status in patients with AS. Dagfinrud et al. [16] also confirmed the benefit of physical therapy including physiotherapy, home exercises, and spa therapy in AS. The same view is presented in the works of Zochling et al. [17] and Wendling et al. [18], who advocate that non-pharmacological treatment of AS should encompass regular exercise, whether through individual or group rehabilitation exercises.

Through our study, we investigated how patients were able to use the potential of rehabilitation to improve their functional status and reduce disease activity after receiving biological treatment. We found that disease activity and functional disability improved in both groups of our patients after receiving appropriate rheumatology and rehabilitation treatment. However, the biological therapy group of patients had a significantly lower rate of functional

disability at the outcome examination compared with the group of patients who received conventional rheumatological treatment. However, there was no significant difference in disease activity between the two groups of patients. Nevertheless, if we consider that the biological therapy group of patients had higher disease activity at the initial examination, this means that their BASDAI improved more (by 5.5 points) than that of the conventional therapy group of patients (Figure 1). Physiotherapy has been shown to be essential for increasing functional status in patients with AS [19].




Figure 1. The extent of reduction in functional disability and disease activity

Notes: Group 1 – the group of patients with conventional treatment, Group 2 – the group of patients with biological treatment, BASFI – Bath Ankylosing Spondylitis Functional Index, BASDAI – Bath Ankylosing Spondylitis Disease Activity Index.

Similar results were reached in the study by Levitova et al. [20], when disease activity, assessed by ASDAS-CRP and BASDAI, exhibited significant improvement in both radiographic and non-radiographic subgroups of AS patients after exercise intervention. Their recommendation is that exercise ought to constitute a vital component of the treatment approach, particularly in the initial phases of the condition. These findings align with research

conducted by other authors [21,22] who have also demonstrated the beneficial effect of exercise on reducing disease activity in patients with AS.

Several randomized controlled trials [23-26] have shown that different types of physical activity exert a beneficial influence on diminishing pain and increasing patients' functional capacity in AS. This result also correlates with the results of our study. Similar results are presented in their reviews by Zochling et al. [27] and Van den Berg [28], where they showed that exercises have a positive effect on functional disability and disease activity, pain and mobility.

Therefore, it is advisable to commence physiotherapy immediately upon the diagnosis of AS, and ongoing regular exercise is fundamental to treatment [29]. Optimal benefit can be achieved with a combination of inpatient spa exercise therapy followed by group physiotherapy, with group physiotherapy being superior and more impactful compared to home exercise. Traditional physiotherapy protocols are advocated, encompassing flexibility, stretching, and breathing exercises, along with pool and/or land exercises.

Based on the results of the study by Tsifetaki [30], individuals diagnosed with AS frequently seek treatment coupled with physical therapy, even when experiencing mild mobility issues. Rehabilitation seems to contribute to enhancing the quality of life for these individuals, though uncertainties persist regarding the required frequency and duration of rehabilitation to sustain its impact.

Our study, despite demonstrating a better effect of physiotherapy in the biological therapy group of patients, has several limitations. One of these is the non-randomized selection of patients. In our region, the population is not high, so the prevalence of spondylarthritis is low. For this reason, we chose the consecutive method of including patients in the study.

The biological therapy group of patients had a significantly lower rate of functional disability in the output results. Considering the information that short disease duration and

patient age ≤ 40 years are predictors of a favorable response to TNFis [5], it follows that these are younger individuals with a shorter disease duration. Therefore, it is less likely that they have degenerative changes in the movement segment that would increase functional disability.

The last limitation is the fact that the biological therapy group of patients had higher disease activity at the initial examination compared to the conventional therapy group of patients. This is because tumor necrosis factor α (TNFis) inhibitors (biological treatment) are recommended solely for patients exhibiting high disease activity [4,5].

Conclusions

The study demonstrated that patients had lower rates of functional disability and disease activity after rheumatic treatment and rehabilitation. Patients who received biological therapy showed better results in the BASFI and BASDAI tests compared to the conventional therapy group of patients, despite having a significantly higher level of disease activity prior to the start of the treatment intervention. Biological treatment has a significant effect on reducing disease activity and allows patients to sufficiently utilize the effect of physiotherapy to increase functional abilities.

Disclosures and acknowledgements

Our thanks go to our colleague Mgr. Ján Petruš for assistance in the implementation of this research.

The authors declare no conflicts of interest with respect to the research, authorship, and/or publication of this article. This research received no specific grant from any funding

agency in the public, commercial, or not-for-profit sectors. Artificial intelligence (AI) was not used in the creation of the manuscript.

References:

1. Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. *Arthritis Care & Research*. 2017; 69(7): 1020-1029. <https://doi.org/10.1002/acr.23233>
2. Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. *Rheumatology*. 2018; 57(suppl. 6): vi4-vi9. <https://doi.org/10.1093/rheumatology/key001>
3. Smith J. Update on ankylosing spondylitis: current concepts in pathogenesis. *Current Allergy and Asthma Reports*. 2015; 15(1): 1-9. <https://doi.org/10.1007/s11882-014-0489-6>
4. Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology /Spondylitis Association of America/ Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2016; 68(2): 282-298. <https://doi.org/10.1002/art.39298>
5. Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. *Semin Arthritis Rheum*. 2017; 47(3): 343-350. <https://doi.org/10.1016/j.semarthrit.2017.04.005>
6. Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, et al. Response to tumor necrosis factor inhibition in male and female patients with

- ankylosing spondylitis: data from a Swiss cohort. *The Journal of Rheumatology*. 2018; 45(4): 506-512. <https://doi.org/10.3899/jrheum.170166>
7. Sharan D, Rajkumar J. Physiotherapy for ankylosing spondylitis: systematic review and a proposed rehabilitation protocol. *Current Rheumatology Reviews*. 2017; 13(2): 121-125. <https://doi.org/10.2174/1573397112666161025112750>
 8. Liang Z, Fu C, Zhang Q, Xiong F, Peng L, Chen L, et al. Effects of water therapy on disease activity, functional capacity, spinal mobility and severity of pain in patients with ankylosing spondylitis: a systematic review and meta-analysis. *Disability and Rehabilitation*. 2019; 43(7): 895-902. <https://doi.org/10.1080/09638288.2019.1645218>
 9. Gur Kabul E, Basakci Calik B, Oztop M, Cobankara V. The efficacy of manual soft-tissue mobilization in ankylosing spondylitis: a randomized controlled study. *International Journal of Rheumatic Diseases*. 2021; 24(3): 445-455. <https://doi.org/10.1111/1756-185X.14072>
 10. Gunay SM, Keser I, Bicer ZT. The effects of balance and postural stability exercises on spa based rehabilitation programme in patients with ankylosing spondylitis. *Journal of Back and Musculoskeletal Rehabilitation*. 2018; 31(2): 337-346. <https://doi.org/10.3233/BMR-169755>
 11. Calin A, Garrett S, Whitelock H, Kennedy LG, O'hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. *The Journal of Rheumatology*. 1994; 21(12): 2281-2285.
 12. Abdal SJ, Yesmin S, Shazzad MN, Azad MAK, Shahin MA, Choudhury MR, et al. Development of a Bangla version of the bath ankylosing spondylitis disease activity index (BASDAI) and the bath ankylosing spondylitis functional index (BASFI).

International Journal of Rheumatic Diseases. 2021; 24(1): 74-80.
<https://doi.org/10.1111/1756-185X.14008>

13. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol.* 1994; 21(12): 2286-2291.
14. Holøyen PK, Stensdotter AK. Patients with spondyloarthritis are equally satisfied with follow-up by physiotherapist and rheumatologist. *Musculoskeletal Care.* 2018; 16(3): 388-397. <https://doi.org/10.1002/msc.1241>
15. Millner JR, Barron JS, Beinke KM, Butterworth RH, Chasle BE, Dutton LJ, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. *Seminars in Arthritis and Rheumatism.* 2016; 45(4): 411-427. <https://doi.org/10.1016/j.semarthrit.2015.08.003>
16. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. *Cochrane Database of Systematic Reviews.* 2008; 23(1): CD002822. <https://doi.org/10.1002/14651858.CD002822.pub3>
17. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Annals of the Rheumatic Diseases.* 2006; 65(4): 442-452. <https://doi.org/10.1136/ard.2005.041137>
18. Wendling D, Lukas C, Paccou J, Claudepierre P, Carton L, Combe B, et al. Recommendations of the French Society of Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. *Joint Bone Spine.* 2014; 81(1): 6-14. <https://doi.org/10.1016/j.jbspin.2013.12.002>
19. Gyurcsik ZN, András A, Bodnár N, Szekanecz Z, Szántó S. Improvement in pain intensity, spine stiffness, and mobility during a controlled individualized physiotherapy

program in ankylosing spondylitis. *Rheumatology International*. 2012; 32: 3931-3936.
<https://doi.org/10.1007/s00296-011-2325-9>

20. Levitova A, Hulejova H, Spiritovic M, Pavelka K, Senolt L, Husakova M. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. *Arthritis Research & Therapy*. 2016; 18(1): 1-12.
<https://doi.org/10.1186/s13075-016-1180-1>
21. Liang H, Li WR, Zhang H, Tian X, Wei W, Wang CM. Concurrent intervention with exercises and stabilized tumor necrosis factor inhibitor therapy reduced the disease activity in patients with ankylosing spondylitis: a meta-analysis. *Medicine*. 2015; 94(50). <https://doi.org/10.1097/MD.0000000000002254>
22. Altan LALE, Korkmaz NİMET, Dizdar M, Yurtkuran M. Effect of Pilates training on people with ankylosing spondylitis. *Rheumatology International*. 2012; 32(7): 2093-2099. <https://doi.org/10.1007/s00296-011-1932-9>
23. Giannotti E, Trainito S, Arioli G, Rucco V, Masiero S. Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. *Clinical Rheumatology*. 2014; 33(9): 1217-1230. <https://doi.org/10.1007/s10067-014-2647-6>
24. Masiero S, Bonaldo L, Pigatto M, Nigro AL, Ramonda R, Punzi L. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy. A randomized controlled trial. *The Journal of Rheumatology*. 2011; 38(7): 1335-1342. <https://doi.org/10.3899/jrheum.100987>
25. Masiero S, Poli P, Bonaldo L, Pigatto M, Ramonda R, Lubrano E, et al. Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up.

Clinical Rehabilitation. 2014; 28(6): 562-572.

<https://doi.org/10.1177/0269215513512214>

26. Kjekken I, Bø I, Rønningen A, Spada C, Mowinckel P, Hagen KB, et al. A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. *Journal of Rehabilitation Medicine*. 2013; 45(3): 260-267. <https://doi.org/10.2340/16501977-1078>
27. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Annals of the Rheumatic Diseases*. 2006; 65(4): 423-432. <https://doi.org/10.1136/ard.2005.041129>
28. Escalas C, Dalichampt M, Dougados M, Poiraudeau S. Evaluation of physiotherapy in a prospective cohort of early axial spondyloarthritis. Data from the DESIR cohort. *Joint Bone Spine*. 2016; 83(2): 185-190. <https://doi.org/10.1016/j.jbspin.2015.05.008>
29. Ozgocmen S, Akgul O, Altay Z, Altindag O, Baysal O, Calis M, et al. Expert opinion and key recommendations for the physical therapy and rehabilitation of patients with ankylosing spondylitis. *International Journal of Rheumatic Diseases*. 2012; 15(3): 229-238. <https://doi.org/10.1111/j.1756-185X.2011.01700.x>
30. Tsifetaki N. The impact of pain on the functionality and mobility of patients with ankylosing spondylitis and the role of physiotherapy in their rehabilitation. *International Journal of Caring Sciences*. 2018; 11(1): 45-52.